Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · ONE GLOBAL SERVICE PROV L · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
ONE GLOBAL SERVICE PROV L
NSE: ONEGLOBAL · BSE: 514330
NSE: ONEGLOBAL · BSE: 514330
Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
ONE GLOBAL SERVICE PROV L
StateQ4 FY26 filed
Last close · 20 Sept 2026₹541.00
Market cap₹1.1k cr
TTM P/E · P/B · EV/EBITDA15.2 · 7.49 · 11.1
ONE GLOBAL SERVICE PROV L is a Healthcare Services company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 6 | 18 | 63 | 147 | 498 |
| EBITDA (ex other income) | 1 | 2 | 10 | 25 | 93 |
| margin % | 22.3 | 9.1 | 15.4 | 17.1 | 18.6 |
| Owners' profit | 1 | 1 | 7 | 19 | 70 |
| EPS, as reported (₹) | 1.48 | 1.94 | 10.01 | 9.45 | 35.56 |
| ROE % · ROCE % | 17.8 · 16.2 | 18.9 · 17.8 | 49.4 · 64.5 | 26.0 · 34.4 | 49.2 · 65.7 |
| Debt / equity (x) | 0.06 | 0.05 | 0.02 | 0.00 | 0.00 |
| Cash from operations | 1 | 0 | 1 | 14 | 3 |
| Capex | (1) | (0) | (0) | (0) | (0) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ONE GLOBAL SERVICE PROV L · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 19 | 33 | 55 | 88 | 135 | 141 | 134 |
| Profit before tax | 2 | 3 | 5 | 15 | 13 | 26 | 29 | 24 |
| Net profit | 2 | 2 | 3 | 11 | 10 | 20 | 22 | 18 |
| EPS (₹) | 2.47 | 3.19 | 4.89 | 5.63 | 5.02 | 10.13 | 11.08 | 9.31 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 32,134 | 46.2 | 12.64 | 37.4 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,919 | 84.9 | 16.63 | 44.4 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,357 | 25.5 | 8.11 | 29.5 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 9,112 | 33.5 | 15.55 | 33.3 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 7,538 | 77.8 | 6.75 | 29.8 | 6.9 | 8.6 | — | 25.3 |
| SURAKSHA DIAGNOSTIC LTD | 1,809 | 50.5 | 7.43 | 18.3 | 12.9 | 11.5 | — | 36.0 |
| KRSNAA DIAGNOSTICS LTD | 1,791 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| 3B BLACKBIO DX LTD. | 1,212 | 20.2 | 3.65 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 15.2 | 22.9 | 10 of 29 | 68% |
| P/B | 7.5 | 2.3 | 19 of 24 | 22% |
| ROCE | 65.7 | 6.1 | 1 of 29 | 100% |
| ROE | 49.2 | 7.3 | 2 of 26 | 96% |
| Debt / Equity | 0.0 | 0.0 | 10 of 26 | 64% |
| EBITDA margin | 18.4 | 25.6 | 14 of 24 | 44% |
| Revenue growth | 141.3 | 20.8 | 2 of 25 | 96% |
| Profit growth | 65.4 | 22.0 | 5 of 25 | 83% |
| Market cap | 1057 | 37 | 9 of 30 | 72% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ONE GLOBAL SERVICE PROV L · 22 September 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 21 Sept 2026 · Corrigendum to 34th AGM Notice: revised preferential issue price | board shareholder meetings | medium | — | — |
| 18 Sept 2026 · Revised pricing for acquisition of 51 percent stakes in Matrix Labs companies | strategic transactions | high | — | — |
| 18 Sept 2026 · Board approves revised pricing for preferential share issue for acquisitions | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Newspaper publication of 34th AGM notice and e-voting information | compliance | minimal | — | — |
| 6 Sept 2026 · Letter dispatch to shareholders without registered emails for AGM | compliance | minimal | — | — |
| 5 Sept 2026 · Book Closure and Record Date set for AGM and Final Dividend | corporate actions | low | — | — |
| 5 Sept 2026 · Record date 22 Sep 2026 set for AGM and final dividend | corporate actions | low | — | — |
| 5 Sept 2026 · AGM on 29 Sep 2026: Re. 1 dividend, Rs. 1000 Cr borrowing limit, acquisition via preferential issue | board shareholder meetings | low | — | — |
| 5 Sept 2026 · AGM notice with FY26 annual report, dividend and key resolutions | board shareholder meetings | medium | — | — |
| 3 Sept 2026 · Board approves 51% stakes in two diagnostics firms and doubles authorised capital | corporate actions | medium | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in